Merck & Company, Inc. vs NovoCure Limited — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
5.4
Bearish
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
NVCR
Healthy balance sheet and financial position.
⚠ currently unprofitable (-26% margin).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $25.21 (+51.7%)
7 analysts
Fundamentals
MRK
NVCR
31.5×
Trailing P/E
—
11.5×
Forward P/E
-14.3×
13.6%
Profit Margin
-25.7%
76.6%
Gross Margin
75.4%
—
ROE
-50.0%
4.9%
Revenue Growth
12.3%
—
Earnings Growth
—
0.28
Beta
0.82
—
Price / Book
—
$277.0B
Market Cap
$1.9B
$73 – $125
52-Week Range
$10 – $20
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →